醒脑静联合盐酸纳洛酮治疗脑出血后昏迷患者的临床疗效

The Clinical Efficacy of Xingnaojing Combined with Naloxone Hydrochloride in the Treatment of Coma after Cerebral Hemorrhage

目的探究醒脑静与盐酸纳洛酮联合应用在治疗脑出血致昏迷患者的临床效果。方法前瞻性方便选取2016年5月—2017年5月收治的82例脑出血致昏迷患者临床资料分析,依治疗模式不同分为对照组(41例)和研究组(41例)。对照组实施盐酸纳洛酮,研究组在盐酸纳洛酮基础上加入醒脑静,比较两组临床疗效、不良反应和临床指标的相关情况。结果研究组治疗总有效率90.24%(37/41)高于对照组53.66%(22/41)有效概率(P<0.05);研究组不良总反应率9.76%(4/41)低于对照组26.84%(11/41)不良反应概率(P<0.05);研究组治疗后GCS指标(13.87±1.82)分与脑血肿量(18.62±3.46)m L相比对照组临床指标优(P<0.05)。结论醒脑静与盐酸纳洛酮联合应用效果较好,能够减弱脑血肿量,降低昏迷指标,药用安全良好,值得普及。

Objective This paper tries to investigate the clinical effect of Xingnaojing combined with naloxone hydrochloride in the treatment of coma in patients with cerebral hemorrhage. Methods The clinical data of 82 patients with cerebral hemorrhage from May 2016 to May 2017 were convenient selected and divided into the control group（41 cases）and the study group（41 cases） according to the treatment pattern. The control group was treated with naloxone hydrochloride,and the study group was treated with Xingnaojing and naloxone hydrochloride. The clinical efficacy, adverse reactions and clinical indexes were compared between the two groups. Results The total effective rate was 90.24%（37/41） in the study group and 53.66%（22/41） in the control group（P〈0.05）. The total adverse reaction rate was 9.76%（4/41） in the study group,lower than that of the control group of 26.84%（11/41）（P〈0.05）. The GCS index was（13.87 ±1.82）points and the amount of hematoma was（18.62±3.46）mL in the study group, significantly higher than those in the control group（P〈0.05）. Conclusion The combination of Xingnaojing and naloxone hydrochloride is effective, which can reduce the amount of hematoma, reduce the coma index, and it is safe, so it is worthy of popularization.